First external quality assurance of antibody diagnostic for SARS-new coronavirus.
Identifieur interne : 002602 ( PubMed/Curation ); précédent : 002601; suivant : 002603First external quality assurance of antibody diagnostic for SARS-new coronavirus.
Auteurs : Matthias Niedrig [Allemagne] ; Katrin Leitmeyer ; Wilina Lim ; Malik Peiris ; John S. Mackenzie ; Maria ZambonSource :
- Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [ 1386-6532 ] ; 2005.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (sang), Assurance de la qualité des soins de santé, Humains, Reproductibilité des résultats, Sensibilité et spécificité, Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (sang), Tests immunologiques (normes), Virus du SRAS (immunologie).
- MESH :
- diagnostic : Syndrome respiratoire aigu sévère.
- immunologie : Syndrome respiratoire aigu sévère, Virus du SRAS.
- normes : Tests immunologiques.
- sang : Anticorps antiviraux, Syndrome respiratoire aigu sévère.
- Assurance de la qualité des soins de santé, Humains, Reproductibilité des résultats, Sensibilité et spécificité.
English descriptors
- KwdEn :
- Antibodies, Viral (blood), Humans, Immunologic Tests (standards), Quality Assurance, Health Care, Reproducibility of Results, SARS Virus (immunology), Sensitivity and Specificity, Severe Acute Respiratory Syndrome (blood), Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (immunology).
- MESH :
- chemical , blood : Antibodies, Viral.
- blood : Severe Acute Respiratory Syndrome.
- diagnosis : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- standards : Immunologic Tests.
- Humans, Quality Assurance, Health Care, Reproducibility of Results, Sensitivity and Specificity.
Abstract
To confirm an infection with the new coronavirus (SARS-CoV) causing the severe acute respiratory syndrome (SARS) diagnostic assays for detection of SARS-CoV specific antibody are necessary. To evaluate the diagnostic performance of laboratories an external quality assurance (EQA) study was performed in 2004. Participating laboratories (9/20) correctly detected anti-SARS antibodies in serum samples without false positive results in an immunofluorescence assay. In contrast, only 4/13 laboratories detected most of the anti-SARS antibody positive samples without false positive results using enzyme immunoassays (EIA) and/or immunoblot. The overall results clearly demonstrate that serological diagnosis of SARS-CoV remains at an early stage of development, with further technical improvements required, particularly with respect to the use of SARS specific EIAs.
DOI: 10.1016/j.jcv.2005.01.004
PubMed: 16087120
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002602
Links to Exploration step
pubmed:16087120Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">First external quality assurance of antibody diagnostic for SARS-new coronavirus.</title>
<author><name sortKey="Niedrig, Matthias" sort="Niedrig, Matthias" uniqKey="Niedrig M" first="Matthias" last="Niedrig">Matthias Niedrig</name>
<affiliation wicri:level="1"><nlm:affiliation>Robert Koch-Institute, Nordufer 20, 13353 Berlin, Germany. niedrigm@rki.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Robert Koch-Institute, Nordufer 20, 13353 Berlin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Leitmeyer, Katrin" sort="Leitmeyer, Katrin" uniqKey="Leitmeyer K" first="Katrin" last="Leitmeyer">Katrin Leitmeyer</name>
</author>
<author><name sortKey="Lim, Wilina" sort="Lim, Wilina" uniqKey="Lim W" first="Wilina" last="Lim">Wilina Lim</name>
</author>
<author><name sortKey="Peiris, Malik" sort="Peiris, Malik" uniqKey="Peiris M" first="Malik" last="Peiris">Malik Peiris</name>
</author>
<author><name sortKey="Mackenzie, John S" sort="Mackenzie, John S" uniqKey="Mackenzie J" first="John S" last="Mackenzie">John S. Mackenzie</name>
</author>
<author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16087120</idno>
<idno type="pmid">16087120</idno>
<idno type="doi">10.1016/j.jcv.2005.01.004</idno>
<idno type="wicri:Area/PubMed/Corpus">002602</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002602</idno>
<idno type="wicri:Area/PubMed/Curation">002602</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002602</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">First external quality assurance of antibody diagnostic for SARS-new coronavirus.</title>
<author><name sortKey="Niedrig, Matthias" sort="Niedrig, Matthias" uniqKey="Niedrig M" first="Matthias" last="Niedrig">Matthias Niedrig</name>
<affiliation wicri:level="1"><nlm:affiliation>Robert Koch-Institute, Nordufer 20, 13353 Berlin, Germany. niedrigm@rki.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Robert Koch-Institute, Nordufer 20, 13353 Berlin</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Leitmeyer, Katrin" sort="Leitmeyer, Katrin" uniqKey="Leitmeyer K" first="Katrin" last="Leitmeyer">Katrin Leitmeyer</name>
</author>
<author><name sortKey="Lim, Wilina" sort="Lim, Wilina" uniqKey="Lim W" first="Wilina" last="Lim">Wilina Lim</name>
</author>
<author><name sortKey="Peiris, Malik" sort="Peiris, Malik" uniqKey="Peiris M" first="Malik" last="Peiris">Malik Peiris</name>
</author>
<author><name sortKey="Mackenzie, John S" sort="Mackenzie, John S" uniqKey="Mackenzie J" first="John S" last="Mackenzie">John S. Mackenzie</name>
</author>
<author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name>
</author>
</analytic>
<series><title level="j">Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</title>
<idno type="ISSN">1386-6532</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (blood)</term>
<term>Humans</term>
<term>Immunologic Tests (standards)</term>
<term>Quality Assurance, Health Care</term>
<term>Reproducibility of Results</term>
<term>SARS Virus (immunology)</term>
<term>Sensitivity and Specificity</term>
<term>Severe Acute Respiratory Syndrome (blood)</term>
<term>Severe Acute Respiratory Syndrome (diagnosis)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (sang)</term>
<term>Assurance de la qualité des soins de santé</term>
<term>Humains</term>
<term>Reproductibilité des résultats</term>
<term>Sensibilité et spécificité</term>
<term>Syndrome respiratoire aigu sévère (diagnostic)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (sang)</term>
<term>Tests immunologiques (normes)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Tests immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Immunologic Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Quality Assurance, Health Care</term>
<term>Reproducibility of Results</term>
<term>Sensitivity and Specificity</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Assurance de la qualité des soins de santé</term>
<term>Humains</term>
<term>Reproductibilité des résultats</term>
<term>Sensibilité et spécificité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To confirm an infection with the new coronavirus (SARS-CoV) causing the severe acute respiratory syndrome (SARS) diagnostic assays for detection of SARS-CoV specific antibody are necessary. To evaluate the diagnostic performance of laboratories an external quality assurance (EQA) study was performed in 2004. Participating laboratories (9/20) correctly detected anti-SARS antibodies in serum samples without false positive results in an immunofluorescence assay. In contrast, only 4/13 laboratories detected most of the anti-SARS antibody positive samples without false positive results using enzyme immunoassays (EIA) and/or immunoblot. The overall results clearly demonstrate that serological diagnosis of SARS-CoV remains at an early stage of development, with further technical improvements required, particularly with respect to the use of SARS specific EIAs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16087120</PMID>
<DateCompleted><Year>2005</Year>
<Month>12</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1386-6532</ISSN>
<JournalIssue CitedMedium="Print"><Volume>34</Volume>
<Issue>1</Issue>
<PubDate><Year>2005</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title>
<ISOAbbreviation>J. Clin. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>First external quality assurance of antibody diagnostic for SARS-new coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>22-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To confirm an infection with the new coronavirus (SARS-CoV) causing the severe acute respiratory syndrome (SARS) diagnostic assays for detection of SARS-CoV specific antibody are necessary. To evaluate the diagnostic performance of laboratories an external quality assurance (EQA) study was performed in 2004. Participating laboratories (9/20) correctly detected anti-SARS antibodies in serum samples without false positive results in an immunofluorescence assay. In contrast, only 4/13 laboratories detected most of the anti-SARS antibody positive samples without false positive results using enzyme immunoassays (EIA) and/or immunoblot. The overall results clearly demonstrate that serological diagnosis of SARS-CoV remains at an early stage of development, with further technical improvements required, particularly with respect to the use of SARS specific EIAs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niedrig</LastName>
<ForeName>Matthias</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Robert Koch-Institute, Nordufer 20, 13353 Berlin, Germany. niedrigm@rki.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Leitmeyer</LastName>
<ForeName>Katrin</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lim</LastName>
<ForeName>Wilina</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Peiris</LastName>
<ForeName>Malik</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mackenzie</LastName>
<ForeName>John S</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zambon</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Clin Virol</MedlineTA>
<NlmUniqueID>9815671</NlmUniqueID>
<ISSNLinking>1386-6532</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007159" MajorTopicYN="N">Immunologic Tests</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011785" MajorTopicYN="N">Quality Assurance, Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>12</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2005</Year>
<Month>01</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2005</Year>
<Month>01</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>8</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16087120</ArticleId>
<ArticleId IdType="pii">S1386-6532(05)00032-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.jcv.2005.01.004</ArticleId>
<ArticleId IdType="pmc">PMC7108360</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Feb 20;314(4):931-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14751221</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2004 Mar;11(2):417-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15013997</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Jul 1;324(2):251-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15207612</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):304-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15030702</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2004 May 15;363(9421):1566-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15145625</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002602 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002602 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:16087120 |texte= First external quality assurance of antibody diagnostic for SARS-new coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16087120" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |